{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:07:09Z","timestamp":1789495629903,"version":"build-2803163510"},"reference-count":118,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.semnephrol.2023.151343","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T05:37:19Z","timestamp":1683178639000},"page":"151343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Amyloidosis and the Kidney: An Update"],"prefix":"10.1016","volume":"42","author":[{"given":"Ralph","family":"Nader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avital","family":"Angel-Korman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Havasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semnephrol.2023.151343_bib0001","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular Mechanisms of Amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"issue":"2-3","key":"10.1016\/j.semnephrol.2023.151343_bib0002","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/jsbi.2000.4221","article-title":"Review: history of the amyloid fibril","volume":"130","author":"Sipe","year":"2000","journal-title":"J Struct Biol"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151343_bib0003","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41580-018-0060-8","article-title":"A new era for understanding amyloid structures and disease","volume":"19","author":"Iadanza","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151343_bib0004","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13506129.2020.1835263","article-title":"Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"27","author":"Benson","year":"2020","journal-title":"Amyloid"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151343_bib0005","first-page":"770","article-title":"Systemic amyloidosis: novel therapies and role of biomarkers","volume":"32","author":"Nuvolone","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151343_bib0006","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000506696","article-title":"The pathology of amyloidosis in classification: a review","volume":"143","author":"Picken","year":"2020","journal-title":"Acta Haematol"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151343_bib0007","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/ndt\/gfy291","article-title":"AL amyloidosis: advances in diagnostics and treatment","volume":"34","author":"Ry\u0161av\u00e1","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"14","key":"10.1016\/j.semnephrol.2023.151343_bib0008","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/circ.104.14.1594","article-title":"Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts","volume":"104","author":"Liao","year":"2001","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151343_bib0009","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ Res"},{"issue":"23","key":"10.1016\/j.semnephrol.2023.151343_bib0010","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1182\/blood-2013-10-525634","article-title":"A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis","volume":"123","author":"Diomede","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151343_bib0011","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/biomedicines7010011","article-title":"Ultrastructure in transthyretin amyloidosis: from pathophysiology to therapeutic insights","volume":"7","author":"Koike","year":"2019","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151343_bib0012","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/TP.0000000000003170","article-title":"Kidney transplantation in systemic amyloidosis","volume":"104","author":"Angel-Korman","year":"2020","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151343_bib0013","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151343_bib0014","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ajh.25149","article-title":"Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment","volume":"93","author":"Gertz","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151343_bib0015","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00256-020-03560-3","article-title":"Amyloidoma: a review and case report","volume":"50","author":"Desai","year":"2021","journal-title":"Skeletal Radiol."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151343_bib0016","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/01.dad.0000211513.98230.74","article-title":"Soft tissue amyloidoma of the extremities: report of a case and review of the literature","volume":"29","author":"Pasternak","year":"2007","journal-title":"Am J Dermatopathol"},{"issue":"24","key":"10.1016\/j.semnephrol.2023.151343_bib0017","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"Quarta","year":"2017","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151343_bib0018","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/archinte.1983.00350080055015","article-title":"Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis","volume":"143","author":"Libbey","year":"1983","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151343_bib0019","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.amjcard.2014.02.030","article-title":"Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis","volume":"113","author":"Fine","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semnephrol.2023.151343_bib0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.humpath.2017.11.001","article-title":"Abdominal fat pad excisional biopsy for the diagnosis and typing of systemic amyloidosis","volume":"72","author":"Garcia","year":"2018","journal-title":"Hum Pathol"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151343_bib0021","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3324\/haematol.2013.102764","article-title":"Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics","volume":"99","author":"Vrana","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151343_bib0022","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1681\/ASN.2006050460","article-title":"Amyloidosis-associated kidney disease","volume":"17","author":"Dember","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151343_bib0023","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/pin.12902","article-title":"Human amyloidosis, still intractable but becoming curable: the essential role of pathological diagnosis in the selection of type-specific therapeutics","volume":"70","author":"Naiki","year":"2020","journal-title":"Pathol Int"},{"issue":"23","key":"10.1016\/j.semnephrol.2023.151343_bib0024","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151343_bib0025","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/13506129.2018.1436048","article-title":"Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR)","volume":"25","author":"Phull","year":"2018","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151343_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2005.08.043","article-title":"Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis","volume":"119","author":"Hazenberg","year":"2006","journal-title":"Am J Med"},{"issue":"24","key":"10.1016\/j.semnephrol.2023.151343_bib0027","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"6\u20137","key":"10.1016\/j.semnephrol.2023.151343_bib0028","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ejheart.2007.01.012","article-title":"Non-invasive predictors of survival in cardiac amyloidosis","volume":"9","author":"Kristen","year":"2007","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151343_bib0029","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/blood.V68.1.220.220","article-title":"Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases","volume":"68","author":"Kyle","year":"1986","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151343_bib0030","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.amjcard.2004.10.028","article-title":"Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement","volume":"95","author":"Murtagh","year":"2005","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151343_bib0031","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0002-9343(77)90870-1","article-title":"The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients","volume":"62","author":"Ridolfi","year":"1977","journal-title":"Am J Med"},{"issue":"13","key":"10.1016\/j.semnephrol.2023.151343_bib0032","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.semnephrol.2023.151343_bib0033","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.3390\/jcm10214888","article-title":"Echocardiographic patterns of left ventricular diastolic function in cardiac amyloidosis: an updated evaluation","volume":"10","author":"Oghina","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151343_bib0034","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.amjcard.2008.09.105","article-title":"Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis","volume":"103","author":"Ruberg","year":"2009","journal-title":"Am J Cardiol."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151343_bib0035","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12350-017-1028-3","article-title":"Nuclear imaging of cardiac amyloidosis","volume":"26","author":"Andrikopoulou","year":"2019","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151343_bib0036","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151343_bib0037","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1182\/blood-2003-12-4192","article-title":"Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study","volume":"103","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.semnephrol.2023.151343_bib0038","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151343_bib0039","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1055\/s-0039-1688994","article-title":"Neuropathy associated with systemic amyloidosis","volume":"39","author":"Kaku","year":"2019","journal-title":"Semin Neurol."},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151343_bib0040","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jhsa.2019.06.016","article-title":"Carpal tunnel syndrome: a potential early, red-flag sign of amyloidosis","volume":"44","author":"Donnelly","year":"2019","journal-title":"J Hand Surg Am"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151343_bib0041","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/ckj\/sfac118","article-title":"Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients","volume":"15","author":"Solignac","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.semnephrol.2023.151343_bib0042","first-page":"1","article-title":"Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden","volume":"590","author":"Andersson","year":"1976","journal-title":"Acta Med Scand Suppl."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151343_bib0043","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.0954-6820.1982.tb03205.x","article-title":"Renal function in familial amyloidosis with polyneuropathy","volume":"212","author":"Steen","year":"1982","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.semnephrol.2023.151343_bib0044","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/brain\/110.2.315","article-title":"Hereditary generalized amyloidosis with polyneuropathy. Clinicopathological study of 65 Japanese patients","volume":"110","author":"Ikeda","year":"1987","journal-title":"Brain."},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151343_bib0045","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0025-6196(12)60388-7","article-title":"Familial amyloidosis: a study of 52 North American-born patients examined during a 30-year period","volume":"67","author":"Gertz","year":"1992","journal-title":"Mayo Clin Proc."},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151343_bib0046","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/jgh.13996","article-title":"Systemic amyloidosis with gastrointestinal involvement: diagnosis from endoscopic and histological views","volume":"33","author":"Iida","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"issue":"145","key":"10.1016\/j.semnephrol.2023.151343_bib0047","doi-asserted-by":"crossref","first-page":"170046","DOI":"10.1183\/16000617.0046-2017","article-title":"The lung in amyloidosis","volume":"26","author":"Milani","year":"2017","journal-title":"Eur Respir Rev"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151343_bib0048","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/PAS.0b013e318272fe19","article-title":"Nodular pulmonary amyloidosis is characterized by localized immunoglobulin deposition and is frequently associated with an indolent B-cell lymphoproliferative disorder","volume":"37","author":"Grogg","year":"2013","journal-title":"Am J Surg Pathol."},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151343_bib0049","doi-asserted-by":"crossref","first-page":"E39","DOI":"10.1053\/ajkd.2001.29295","article-title":"Polyglandular endocrine failure in a patient with amyloidosis secondary to familial Mediterranean fever","volume":"38","author":"Keven","year":"2001","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151343_bib0050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ckj\/sfu021","article-title":"Amyloid nephropathy","volume":"7","author":"Khalighi","year":"2014","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151343_bib0051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1523-1755.2002.00085.x","article-title":"Immunoglobulin light chain amyloidosis and the kidney","volume":"61","author":"Gertz","year":"2002","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151343_bib0052","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bbapap.2005.08.014","article-title":"Clinical aspects of systemic amyloid diseases","volume":"1753","author":"Obici","year":"2005","journal-title":"Biochim Biophys Acta."},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151343_bib0053","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1093\/ndt\/gfq831","article-title":"Renal amyloidosis revisited: amyloid distribution, dynamics and biochemical type","volume":"26","author":"Hopfer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151343_bib0054","doi-asserted-by":"crossref","first-page":"E45","DOI":"10.1002\/ajh.25685","article-title":"Systemic AL amyloidosis with an undetectable plasma cell dyscrasia: a zebra without stripes","volume":"95","author":"Staron","year":"2020","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151343_bib0055","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/ki.2012.414","article-title":"The diagnosis and characteristics of renal heavy-chain and heavy\/light-chain amyloidosis and their comparison with renal light-chain amyloidosis","volume":"83","author":"Nasr","year":"2013","journal-title":"Kidney Int."},{"issue":"15","key":"10.1016\/j.semnephrol.2023.151343_bib0056","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151343_bib0057","doi-asserted-by":"crossref","first-page":"E458","DOI":"10.1002\/ajh.24464","article-title":"Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation","volume":"91","author":"Havasi","year":"2016","journal-title":"Am J Hematol."},{"issue":"36","key":"10.1016\/j.semnephrol.2023.151343_bib0058","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151343_bib0059","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151343_bib0060","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.08720811","article-title":"Transthyretin amyloidosis and the kidney","volume":"7","author":"Lobato","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"23","key":"10.1016\/j.semnephrol.2023.151343_bib0061","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151343_bib0062","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/13506129.2017.1350158","article-title":"Kidney biopsy in AA amyloidosis: impact of histopathology on prognosis","volume":"24","author":"Kendi Celebi","year":"2017","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151343_bib0063","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/13506129.2017.1342235","article-title":"Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre","volume":"24","author":"Lane","year":"2017","journal-title":"Amyloid."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151343_bib0064","first-page":"241","article-title":"Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis","volume":"33","author":"Rezk","year":"2018","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151343_bib0065","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/ki.2013.558","article-title":"Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis","volume":"86","author":"Said","year":"2014","journal-title":"Kidney Int."},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151343_bib0066","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.2215\/CJN.12551214","article-title":"Leukocyte cell\u2013derived chemotaxin 2\u2013associated amyloidosis: a recently recognized disease with distinct clinicopathologic characteristics","volume":"10","author":"Nasr","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151343_bib0067","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1681\/ASN.2005040382","article-title":"Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis","volume":"16","author":"Gregorini","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151343_bib0068","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ekir.2017.07.009","article-title":"Hereditary renal amyloidosis associated with a novel apolipoprotein A-II variant","volume":"2","author":"Prokaeva","year":"2017","journal-title":"Kidney Int Rep."},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151343_bib0069","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.kint.2016.04.003","article-title":"Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis","volume":"90","author":"Dasari","year":"2016","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151343_bib0070","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1681\/ASN.2015111228","article-title":"Novel type of renal amyloidosis derived from apolipoprotein-CII","volume":"28","author":"Nasr","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151343_bib0071","doi-asserted-by":"crossref","first-page":"10353","DOI":"10.1038\/ncomms10353","article-title":"D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile","volume":"7","author":"Valleix","year":"2016","journal-title":"Nat Commun."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151343_bib0072","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1681\/ASN.2016090951","article-title":"Hereditary lysozyme amyloidosis variant p.Leu102Ser associates with unique phenotype","volume":"28","author":"Nasr","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.semnephrol.2023.151343_bib0073","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/13506129.2022.2072198","article-title":"Lysozyme amyloidosis-a report on a large German cohort and the characterisation of a novel amyloidogenic lysozyme gene variant","volume":"29","author":"Anker","year":"2022","journal-title":"Amyloid."},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151343_bib0074","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2796.2011.02470.x","article-title":"Hereditary lysozyme amyloidosis \u2013 phenotypic heterogeneity and the role of solid organ transplantation","volume":"272","author":"Sattianayagam","year":"2012","journal-title":"J Intern Med"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151343_bib0075","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3109\/07853890.2015.1075063","article-title":"Natural course of Finnish gelsolin amyloidosis","volume":"47","author":"Nikoskinen","year":"2015","journal-title":"Ann Med"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151343_bib0076","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/13506129.2019.1604336","article-title":"Amyloid in parenchymal organs in gelsolin (AGel) amyloidosis","volume":"26","author":"Schmidt","year":"2019","journal-title":"Amyloid."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151343_bib0077","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.2008060614","article-title":"Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A\u03b1-chain amyloidosis","volume":"20","author":"Gillmore","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151343_bib0078","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3109\/13506129.2013.781998","article-title":"Hereditary amyloidosis caused by R554L fibrinogen A\u03b1-chain mutation in a Spanish family and review of the literature","volume":"20","author":"Haidinger","year":"2013","journal-title":"Amyloid."},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151343_bib0079","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.transproceed.2016.04.015","article-title":"Comparative analysis of outcomes of kidney transplantation in patients with AA amyloidosis and chronic glomerulonephritis","volume":"48","author":"Sahutoglu","year":"2016","journal-title":"Transplant Proc"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151343_bib0080","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2215\/CJN.10491012","article-title":"Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases","volume":"8","author":"Said","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151343_bib0081","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/modpathol.2016.29","article-title":"Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a common form of renal amyloidosis among Egyptians","volume":"29","author":"Larsen","year":"2016","journal-title":"Mod Pathol."},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151343_bib0082","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/ki.1997.262","article-title":"Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study","volume":"51","author":"Jadoul","year":"1997","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151343_bib0083","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1046\/j.1523-1755.2003.00235.x","article-title":"Effect of beta(2)-microglobulin adsorption column on dialysis-related amyloidosis","volume":"64","author":"Abe","year":"2003","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151343_bib0084","doi-asserted-by":"crossref","first-page":"100427","DOI":"10.1016\/j.xkme.2022.100427","article-title":"Correlation between 24-hour urine protein and random urine protein-creatinine ratio in amyloid light-chain amyloidosis","volume":"4","author":"Mendelson","year":"2022","journal-title":"Kidney Med"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151343_bib0085","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/PAP.0b013e3182a92dc3","article-title":"Modern approaches to the treatment of amyloidosis: the critical importance of early detection in surgical pathology","volume":"20","author":"Picken","year":"2013","journal-title":"Adv Anat Pathol."},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151343_bib0086","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1053\/j.ajkd.2015.10.006","article-title":"AJKD atlas of renal pathology: AL amyloidosis","volume":"66","author":"Fogo","year":"2015","journal-title":"Am J Kidney Dis."},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151343_bib0087","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","article-title":"Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples","volume":"95","author":"Dasari","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151343_bib0088","first-page":"280","article-title":"Light chain amyloidosis: a case presentation and review","volume":"22","author":"Melmed","year":"2009","journal-title":"Proc (Bayl Univ Med Cent)."},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151343_bib0089","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1093\/ndt\/gfh503","article-title":"AL-amyloidosis is underdiagnosed in renal biopsies","volume":"19","author":"Novak","year":"2004","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151343_bib0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41408-021-00486-4","article-title":"Comprehensive review of AL amyloidosis: some practical recommendations","volume":"11","author":"Al Hamed","year":"2021","journal-title":"Blood Cancer J."},{"issue":"suppl 1","key":"10.1016\/j.semnephrol.2023.151343_bib0091","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1182\/blood-2019-127004","article-title":"In systemic light-chain amyloidosis complete and very good partial responses are not enough: involved free light chain (iFLC) levels < 10mg\/L are associated with optimal long-term survival","volume":"134","author":"Godara","year":"2019","journal-title":"Blood."},{"issue":"25","key":"10.1016\/j.semnephrol.2023.151343_bib0092","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood."},{"issue":"17","key":"10.1016\/j.semnephrol.2023.151343_bib0093","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151343_bib0094","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","article-title":"Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only","volume":"100","author":"Skinner","year":"1996","journal-title":"Am J Med"},{"issue":"20","key":"10.1016\/j.semnephrol.2023.151343_bib0095","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151343_bib0096","first-page":"1445","article-title":"Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for light chain amyloidosis: results of a prospective clinical trial, Biol Blood Marrow","volume":"21","author":"Sanchorawala","year":"2015","journal-title":"Transplant."},{"issue":"32","key":"10.1016\/j.semnephrol.2023.151343_bib0097","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a center for international blood and marrow transplant research study","volume":"33","author":"D\u2019Souza","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2023.151343_bib0098","doi-asserted-by":"crossref","first-page":"907584","DOI":"10.3389\/fonc.2022.907584","article-title":"Supportive care and symptom management for patients with immunoglobulin light chain (AL) amyloidosis","volume":"12","author":"Jensen","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151343_bib0099","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1046\/j.1523-1755.2003.00936.x","article-title":"Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis","volume":"63","author":"Fadia","year":"2003","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151343_bib0100","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/ndt\/gfab189","article-title":"Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis","volume":"37","author":"Nader","year":"2022","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151343_bib0101","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151343_bib0102","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ajh.26399","article-title":"Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab","volume":"97","author":"Szalat","year":"2022","journal-title":"Am J Hematol"},{"issue":"15_suppl","key":"10.1016\/j.semnephrol.2023.151343_bib0103","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2021.39.15_suppl.8003","article-title":"Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: updated results from the phase 3 ANDROMEDA study","volume":"39","author":"Kastritis","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151343_bib0104","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cam4.3683","article-title":"AL amyloidosis: the effect of fluorescent in situ hybridization abnormalities on organ involvement and survival","volume":"10","author":"Ozga","year":"2021","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151343_bib0105","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/13506129.2020.1778461","article-title":"Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen","volume":"27","author":"Dumas","year":"2020","journal-title":"Amyloid."},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151343_bib0106","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacbts.2019.02.002","article-title":"Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis","volume":"4","author":"Zhang","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.semnephrol.2023.151343_bib0107","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fimmu.2011.00032","article-title":"Generation and characterization of anti-AA amyloid-specific monoclonal antibodies","volume":"2","author":"Wall","year":"2011","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151343_bib0108","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/hemato3010012","article-title":"Future developments in the treatment of AL amyloidosis","volume":"3","author":"Theodorakakou","year":"2022","journal-title":"Hemato."},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151343_bib0109","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-022-00714-5","article-title":"Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group","volume":"12","author":"Havasi","year":"2022","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151343_bib0110","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1523-1755.2004.00485.x","article-title":"Renal amyloidosis in familial Mediterranean fever","volume":"65","author":"Ozen","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151343_bib0111","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pathol-020712-163913","article-title":"AA amyloidosis: pathogenesis and targeted therapy","volume":"10","author":"Westermark","year":"2015","journal-title":"Annu Rev Pathol."},{"issue":"9275","key":"10.1016\/j.semnephrol.2023.151343_bib0112","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0140-6736(00)05252-1","article-title":"Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein","volume":"358","author":"Gillmore","year":"2001","journal-title":"Lancet."},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151343_bib0113","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1111\/j.1600-6143.2011.03620.x","article-title":"Renal transplantation in patients with AA amyloidosis nephropathy: results from a French multicenter study","volume":"11","author":"Kofman","year":"2011","journal-title":"Am J Transplant."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151343_bib0114","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0272-6386(03)00676-0","article-title":"Long-term outcome of live donor kidney transplantation for renal amyloidosis","volume":"42","author":"Sherif","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"suppl 1","key":"10.1016\/j.semnephrol.2023.151343_bib0115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/13506129.2012.668503","article-title":"Solid organ transplantation for non-TTR hereditary amyloidosis: report from the 1st International Workshop on the Hereditary Renal Amyloidoses","volume":"19","author":"Stangou","year":"2012","journal-title":"Amyloid."},{"key":"10.1016\/j.semnephrol.2023.151343_bib0116","doi-asserted-by":"crossref","DOI":"10.1016\/j.kint.2018.09.021","article-title":"Long-term outcome of kidney transplantation in AL amyloidosis","author":"Angel-Korman","year":"2019","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151343_bib0117","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/ki.2012.180","article-title":"The pathophysiology of edema formation in the nephrotic syndrome","volume":"82","author":"Siddall","year":"2012","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151343_bib0118","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ajh.23898","article-title":"Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis","volume":"90","author":"Kaufman","year":"2015","journal-title":"Am J Hematol"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523000530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523000530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:41:19Z","timestamp":1759448479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929523000530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":118,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0270929523000530"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151343","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amyloidosis and the Kidney: An Update","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151343","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151343"}}